The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Launch of new AIDSInfo Website
On December 2, 2002, the HIV/AIDS Clinical Trials Information Service (ACTIS) and its sister service, the HIV/AIDS Treatment Information Service (ATIS), will be merged into a single website called AIDSinfo.nih.gov. The AIDSinfo project will include all of the services already available from ACTIS and ATIS, as well as added quick and easy access to wide-ranging Federal resources on HIV/AIDS clinical research, HIV treatment and prevention, and medical practice guidelines for health care providers and consumers.
The AIDSinfo Web site, located at AIDSinfo.nih.gov, is designed for full accessibility, ensuring easy search and navigation. The Web site presents federally approved information on HIV/AIDS treatment and prevention guidelines, a comprehensive database of both government and industry-supported HIV/AIDS clinical trials, and information about approved and experimental HIV/AIDS drugs, and vaccines. The site's Education and Resource Center is a virtual one-stop shop offering links and other downloadable resources specially designed for patients, researchers, health care providers, and the general public.
An AIDSinfo Telephone Help Line will provide access to English- and Spanish-speaking Health Information Specialists who offer confidential responses to questions, and assistance with navigating the Web site. The Help Line is available Monday through Friday, noon to 5:00 p.m., Eastern Time.
AIDSinfo E-news, an electronic newsletter, will keep you informed about new and updated treatment guidelines, clinical trials, drugs, and Web site updates. If you already subscribe to the ATIS listserv, you will automatically be placed on the AIDSinfo E-news subscriber list. If not, please visit the AIDSinfo Web site on or after December 2 to subscribe.
Plan to visit the AIDSinfo Web site on or after December 2, or call to learn more about this exciting new service.
Office of Special Health Issues
Food and Drug Administration